FibroBoost Featuring Seanol 400 mg [Discontinued] by Doctor's Best

POSSIBLY EFFECTIVE

• Hypercholesterolemia. Oral Ecklonia cava seems to reduce levels of low-density lipoprotein (LDL) cholesterol. Details: Clinical research in patients with hypercholesterolemia shows that taking Ecklonia cava polyphenols (Botamedi Inc.) 200 mg twice daily for 12 weeks reduces LDL cholesterol by 11% when compared with taking placebo (106336). Also, preliminary clinical research in patients with hypercholesterolemia shows that taking a different Ecklonia cava polyphenol extract (Seapolynol, Livechem, Inc.) 400 mg once daily for 12 weeks reduces levels of LDL cholesterol by 9% when compared with baseline (106335). In overweight adults, many with hypercholesterolemia, clinical research shows that taking Ecklonia cava polyphenols 72 mg or 144 mg daily for 12 weeks reduces LDL cholesterol levels by 10% and 14%, respectively, when compared with placebo (96376). Taking Ecklonia cava does not seem to increase levels of high-density lipoprotein (HDL) cholesterol or reduce levels of triglycerides (96376,106335,106336).

INSUFFICIENT RELIABLE EVIDENCE to RATE

• Asthma. Although there is interest in using oral Ecklonia cava for asthma, there is insufficient reliable information about the clinical effects of Ecklonia cava for this condition.
• Athletic performance. It is unclear if oral Ecklonia cava is beneficial for improving athletic performance. Details: Preliminary clinical research in male college students shows that taking Ecklonia cava polyphenols 72 mg as part of 180 mL of a sport drink 30 minutes before exercise increases the time to exhaustion by approximately 2.4 minutes when compared with the sport drink alone (96377).
• Cancer. Although there is interest in using oral Ecklonia cava for cancer, there is insufficient reliable information about the clinical effects of Ecklonia cava for this condition.
• Cardiovascular disease (CVD). Although there is interest in using oral Ecklonia cava for CVD, there is insufficient reliable information about the clinical effects of Ecklonia cava for this condition.
• Diabetes. Although there is interest in using oral Ecklonia cava for diabetes, there is insufficient reliable information about the clinical effects of Ecklonia cava for this condition.
• Erectile dysfunction (ED). Although there is interest in using oral Ecklonia cava for ED, there is insufficient reliable information about the clinical effects of Ecklonia cava for this condition.
• Fatigue. Although there is interest in using oral Ecklonia cava for various causes of fatigue, there is insufficient reliable information about the clinical effects of Ecklonia cava for this use.
• Fibromyalgia. Although there is interest in using oral Ecklonia cava for fibromyalgia, there is insufficient reliable information about the clinical effects of Ecklonia cava for this use.
• Impaired glucose tolerance (prediabetes). It is unclear if oral Ecklonia cava is beneficial for prediabetes. Details: Preliminary clinical research in adults with prediabetes shows that taking a specific Ecklonia cava extract (AG-dieckol, Aqua Green Tech Co.) 500 mg three times daily for 12 weeks reduces postprandial glucose levels by 5.5%, compared with a small increase in those taking placebo. However, Ecklonia cava extract did not improve fasting blood glucose, insulin sensitivity, or glycated hemoglobin (HbA1c) when compared with placebo (96375).
• Insomnia. Although there is interest in using oral Ecklonia cava for insomnia, there is insufficient reliable information about the clinical effects of Ecklonia cava for this use.
• Male infertility. Although there is interest in using oral Ecklonia cava for male infertility, there is insufficient reliable information about the clinical effects of Ecklonia cava for this condition.
• Metabolic syndrome. Although there is interest in using oral Ecklonia cava for metabolic syndrome, there is insufficient reliable information about the clinical effects of Ecklonia cava for this condition.
• Neuropathic pain. Although there is interest in using oral Ecklonia cava for neuropathic pain, there is insufficient reliable information about the clinical effects of Ecklonia cava for this condition.
• Obesity. It is unclear if oral Ecklonia cava polyphenols improve weight loss or body composition; the available research is conflicting. Details: A small clinical trial in individuals with a body mass index (BMI) between 25 kg/m2 and 30 kg/m2 shows that taking Ecklonia cava polyphenols (Seapolynol, Botamedi Inc.) 180 mg twice daily for 12 weeks does not reduce body weight, BMI, body fat percentage, or low-density lipoprotein (LDL) cholesterol levels when compared with placebo. However, in a sub-group of patients with abdominal obesity, Ecklonia cava modestly reduced total adipose tissue levels and fat mass and increased skeletal muscle mass when compared with placebo. All patients in this study increased physical activity and consumed a diet with a mild caloric restriction (106334). Conversely, other clinical research in a similar population shows that taking Ecklonia cava polyphenols 144 mg daily for 12 weeks reduces body fat ratio by 7% and body weight, BMI, and waist circumference by 2%. These improvements were statistically significant when compared with placebo. Furthermore, taking Ecklonia cava polyphenols 72 mg or 144 mg daily reduces LDL cholesterol levels by 10% and 14%, respectively, when compared with placebo (96376). The reasons for these discrepant findings are unclear.
• Osteoarthritis. Although there is interest in using oral Ecklonia cava for osteoarthritis, there is insufficient reliable information about the clinical effects of Ecklonia cava for this condition.
• Radiation exposure. Although there is interest in using oral Ecklonia cava for radiation exposure due to its iodine content, there is insufficient reliable information about the clinical effects of Ecklonia cava for this use. More evidence is needed to rate Ecklonia cava for these uses.

(Read more about ECKLONIA CAVA)

POSSIBLY SAFE ...when a specific Ecklonia cava phlorotannin extract (SeaPolynol) is used orally and appropriately. Doses of up to 400 mg daily have been used with apparent safety for 12 weeks (106334,106336). According to the European Food Safety Authority (EFSA), doses of up to 263 mg daily are considered safe based on extrapolation from animal toxicity research (106333). ...when other sources of Ecklonia cava polyphenols are used orally, short-term. Doses up to 144 mg daily have been used with apparent safety for up to 12 weeks (96376). ...when a specific Ecklonia cava polyphenol-rich extract (AG-dieckol, Aqua Green Tech Co.) is used orally and appropriately. Doses of up to 1500 mg daily have been used with apparent safety for up to 12 weeks (96375).

CHILDREN: POSSIBLY SAFE
when a specific Ecklonia cava phlorotannin extract (SeaPolynol) is used orally and appropriately in children 12 years and older. According to the EFSA, doses of up to 163 mg daily are considered safe in children aged 12-14 years, and 230 mg daily is considered safe in children aged 14 years and above, based on extrapolation from animal toxicity research (106333). There is insufficient reliable information available about the safety of Ecklonia cava in children under 12 years of age.

PREGNANCY AND LACTATION:
Insufficient reliable information available; avoid using.

(Read more about ECKLONIA CAVA)

(Read more about ECKLONIA CAVA)

General ...Orally, Ecklonia cava extract and Ecklonia cava polyphenols seem to be well tolerated.

Dermatologic ...Orally, alopecia has been reported by one person in a clinical trial (106335).

Gastrointestinal ...Orally, nausea, dyspepsia, and diarrhea have been reported by one person each in a clinical trial (106335).

(Read more about ECKLONIA CAVA)